Ogden, UTAH – According to the state officials, Cannabinoids, such as delta-9 THC and CBD, are generally regarded as the primary active ingredients in hemp and cannabis products.
Officials also said that because delta-9-THC, CBD, and a few other cannabinoids that are more abundant in cannabis plants have been used by humans for thousands of years, the potential of these cannabinoids to directly harm those who use them is generally considered to be low.
Other cannabinoids which are not generally present or are less abundant in cannabis plants, do not have the same history supporting their safety.
While the health effects of these minor cannabinoids are unknown, some negative health outcomes have been reported.
These minor cannabinoids can now be obtained by producers in much greater quantities using selective genetic techniques or semi-synthetic/synthetic production.
These cannabinoids have not been sufficiently used or researched and are considered poorly characterized. The presence of large amounts of some of these poorly characterized cannabinoids in hemp and medical cannabis products is concerning to UDAF because their safety is unknown.
This is especially true of cannabinoids that are produced semi-synthetically/synthetically because they are frequently produced in poorly controlled conditions and may contain other unidentified contaminants.
Due to recent increases in the availability of products that contain poorly characterized cannabinoids, UDAF is providing the following clarifications and information for consumers for both hemp and cannabis products.